Program
vapendavir
Also written as “Vapendavir”, “VPV 1000 mg” and “vapendavir 132 mg capsule”.
Its studies are mostly in Enterovirus Infections · Pulmonary Disease, Chronic Obstructive · Asthma · Respiratory Tract Infections, led by 3 companies.
Drug pageVapendavir: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Altesa Biosciences | 41 open or running | phase 2since Oct 11, 2023 | Jun 7, 2023 | Nov 15, 2027phase 2 · NCT07610395 |
| Vaxartits history only | 40 open or running | phase 2since Feb 13, 2015 | Mar 24, 2014 | none ahead |
| Biota Scientific Management Ptyits history only | 20 open or running | phase 2since Aug 3, 2010 | Aug 3, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Altesa Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 7, 2023First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05962645 · 21 enrolled · United States
- Oct 11, 2023Phase 2 study in Virus DiseasesNCT06149494 · 52 enrolled · United Kingdom
- Feb 11, 2025Phase 2 study in Healthy MalesNCT06834295 · 8 enrolled · United Kingdom
- May 12, 2026Phase 2 study in Rhinovirus InfectionNCT07610395 · 180 planned · United States, United Kingdom
Ahead
- Nov 15, 2027Primary completion: phase 2 study in Rhinovirus InfectionNCT07610395
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“VP1 capsid protein inhibitor”ChEMBL 37, by rule
Studies
All 4 Altesa Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07610395Rhinovirus Infection · United States, United Kingdom | 2 | Recruiting | Nov 15, 2027 | 180 |
| NCT06834295Healthy Males · United Kingdom | 2 | Completed | Mar 23, 2025 | 8 |
| NCT06149494Virus Diseases · United Kingdom | 2 | Completed | Mar 30, 2025 | 52 |
| NCT05962645Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Dec 12, 2023 | 21 |
How it is read
Names in the registry
- “Vapendavir”, 6 entries
- “VPV 1000 mg”, 1 entry
- “vapendavir 132 mg capsule”, 1 entry
- “vapendavir 264 mg tablet”, 1 entry
- “vapendavir 24 mg/mL oral suspension”, 1 entry
Conditions, from the studies’ own filings
- Enterovirus Infections, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
- Asthma, 1 study
- Respiratory Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.